Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 14 of 24, showing 10 Applications out of 238 total, starting on record 131, ending on 140

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

131.

ECCT/21/12/05   131 Inclacumab Ph 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Videlis N Nduba
4. Prof. Jessie N Githanga
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
 
22-03-2022 View

132.

ECCT/22/01/01   ASTEFANIA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY   
Principal Investigator(s)
1. Mansoor Saleh
2. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
21-07-2022 View

133.

ECCT/22/01/06   AIKILI Technology
    Feasibility and accuracy of nanosensor-based breast cancer diagnosis at the point-of-care-AIKILI technology       
Principal Investigator(s)
1. Laura Kelley Kelley
Site(s) in Kenya
Aga Khan University Hospital, Nairobi.
 
21-03-2022 View

134.

ECCT/22/01/03   lidERA
    A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
1. International Cancer Institute (ICI) (Uasin Gishu county)
2. Aga Khan University Hospital (Nairobi City county)
 
08-05-2022 View

135.

ECCT/21/11/01   VAT 00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older   
Principal Investigator(s)
1. Walter Godfrey Jaoko
Site(s) in Kenya
1. Kenya Medical Research Institute (Kisumu county)
2. KEMRI/Walter Reed Project Research Center (Kericho county)
3. KEMRI/CCR Partners in Health R&D (PHRD) (Kiambu county)
4. KEMRI CMR (Kisumu county)
5. Kenya Medical Research Institute (Nairobi City county)
6. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
7. Moi University Clinical Research Centre (Uasin Gishu county)
8. Aga Khan University Hospital (Nairobi City county)
9. KEMRI CCR-Butere County Hospital Site (Kakamega county)
10. Ganjoni Clinic (Mombasa county)
 
15-01-2022 View

136.

ECCT/21/11/07   lidERA
    A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTORPOSITIVE, HER2-NEGATIVE EARLY BREAST CANCER   
Principal Investigator(s)
1. Fredrick Asirwa Chite
Site(s) in Kenya
1. International Cancer Institute (ICI) (Uasin Gishu county)
2. Aga Khan University Hospital (Nairobi City county)
 
27-03-2022 View

137.

ECCT/21/10/05   Lactolize Study
    Lactoferrin and Lysozyme supplementation for long-term diarrhea sequelae   
Principal Investigator(s)
1. Benson Ochieng Singa
Site(s) in Kenya
1. Awendo Sub-County Hospital (Migori county)
2. Homa Bay County Referral Hospital (Homa Bay county)
3. Isebania Sub-County Hospital (Migori county)
4. Kendu Adventist Hospital (Homa Bay county)
5. Kisii Teaching and Referral Hospital (Kisii county)
6. Mbita Sub-County Hospital (Homa Bay county)
7. Rongo Sub-County Hospital (Migori county)
 
13-06-2022 View

138.

ECCT/22/01/05   STEP-Mag Trial
    Simplified Treatment for Eclampsia Prevention using Magnesium sulfate:  A phase III, randomized, open label, active controlled, multicountry, multicentre, non-inferiority trial of simplified magnesium sulfate regimen for eclampsia prophylaxis (The STEP-Mag Trial)   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Wamalwa Kijana TRH (Trans Nzoia county)
2. Mama Lucy Kibaki Hospital (Nairobi City county)
3. Mbagathi County referral Hospital (Nairobi City county)
 
15-05-2022 View

139.

ECCT/21/11/04   GBT_131 Inclacumab-Ps 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises   
Principal Investigator(s)
1. Fredrick Sirwa Chite
2. Prof Jessie N Githanga
3. Bernhards Ragama Ogutu
4. Videlis N Nduba
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. Strathmore University Medical Centre (Nairobi City county)
 
21-12-2021 View

140.

ECCT/21/09/04   Recombinant COVID-19 Vaccine
    A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells) for the prevention of COVID-19 in adults aged 18 years and older            
Principal Investigator(s)
1. Sylvester Kimaiyo
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (Nairobi City county)
2. Moi Teaching and Referral Hospital (Uasin Gishu county)
3. Kenya Medical Research Institute, Kilifi (Kilifi county)
 
17-09-2021 View